Epithelial ovarian cancer: in the NCT01637532 phase I trial, Tocilizumab in association with interferon-α2b and carboplatin/doxorubicin showed a good safety profile. Its antitumor activity remains to be explored in a following phase II trial [62].Renal cell carcinoma: in preclinical in vitro and in vivo (xenograft) studies, Tocilizumab significantly suppressed cell proliferation, due to its capacity to suppress SOCS3 expression, a negative regulator of the JAK-STAT pathway [63]. This evidence concerns the gene SOAT1 and ovarian carcinoma.